Dry eye disease (DED) is a chronic inflammatory condition affecting 334 million people worldwide.
Cyclosporine is an immunosuppressant commonly used to treat DED by increasing tear production and improving tear film stability. Due to cyclosporine’s hydrophobic properties, current drug formulations rely on oil-in-water emulsions to deliver the drug to the tissues in the eye. This type of formulation is known to cause eye irritation, like a burning sensation, upon application.
IC 133 is a novel nano-enabled form of cyclosporine which is being developed for the treatment of dry eye. It uses nanoparticles of biocompatible polymers to wrap and solubilize cyclosporine in a protective cover, helping it across the barriers of the eye.